Neuroleptic malignant syndrome in Mexico

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 3, 2003, Pages 111-113

  Montoya, Alonso ^a,b   Ocampo, Magdalena ^b   Torres Ruiz, Antonio ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Frequency; Incidence; Neuroleptic malignant syndrome; Neuroleptics; NMS

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; MIDAZOLAM; NEUROLEPTIC AGENT; PIPOTIAZINE PALMITATE;

ADOLESCENT; ADULT; ARTICLE; CEREBELLUM DISEASE; CLINICAL FEATURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEXICO; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; TREMOR; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEXICO; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0141904741     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Delay J, Pichot P, Lemperiere T, Elissade B, Peigne F. Un neuroleptique majeur non-phenothiazine et non reserpinique, l'haloperidol, dans le traitement des psychoses. Ann Medico-Psychologique 1960;118:145-52.
2. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
3. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;43:1587-90.
4. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: A prospective study. Am J Psychiatry 1990;147:1149-55.
5. Gelenberg AJ, Bellinghausen B, Wojcil JD, Falk WE, Sachs GE. A prospective study of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 1988;145:517-8.
6. Hermesh H, Aizenberg D, Weizman A, Lapidot A, Mayor K, Munitz H. Risk for definite neuroleptic malignant syndrome: A prospective study in 223 consecutive inpatients. Br J Psychiatry 1992;161:254-7.
7. Keck PE, Pope HG, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: A prospective study. Am J Psychiatry 1987;144:1344-6.
8. Keck PE, Pope HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-2.
9. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington: American Psychiatric Association, 2000.
10. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
11. First, MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV patient edition (SCID-I/P V and SCID-I/NP Version 2.0). New York: Biometric Research Department, 1998.
12. Caroff SN, Mann SC, Campbell EA. The neuroleptic malignant syndrome. In: Adverse Drug Reaction Bulletin, No. 209. Philadelphia: Lippincott Williams & Wilkins, 2001:799-802.
13. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic Malignant Syndrome: A Review. Psychiatric Services 1998;49:1163-72.
14. Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res 2002;33:572-80.